Kevin Hern introduced a bill this week to shore up acute-care hospital resources, which is a fine thing for a member of the House Ways and Means Health subcommittee to do. It's also, per his public disclosure record, a fine thing for a member who has been trading healthcare stocks in industries that fall directly under his committee's jurisdiction. The bill is called the Saving Today's Acute-Care Resources Act. The trades are in the filings. The connection is yours to make.
The Bill, in Brief
H.R. 9468 aims to preserve acute-care hospital capacity. Hern sits on the Ways and Means Committee's Health subcommittee, which means acute-care reimbursement, Medicare payment structures, and hospital finance policy are his lane by job description. The bill is a natural product of that assignment.
It also positions Hern as a visible friend to the hospital industry at a moment when hospital-sector stocks are under pressure from a cascade of policy headwinds. The calendar and the filing cabinet speak for themselves.
What the Trades Actually Show
Hern has filed 5 disclosed trades in the last 90 days. The May 8 cluster is the most notable: he executed exchanges and sales on both Coterra Energy (CTRA) and Devon Energy (DVN), each in the $15,001 to $50,000 range. Two sells on two oil-and-gas names on the same day.
Then there's the Goldman Sachs (GS) sale on April 29: $250,000 to $500,000. A meaningful exit from a financial-sector name that landed before the Ways and Means Tax subcommittee's recent busy season. Hern also sits on Tax. Goldman's fortunes are not unrelated to what comes out of that room.
To be clear: there are no flagged vote-trade overlaps in the current data. The timing of these specific sales doesn't line up with a committee vote we can point to directly. The trades are trades. They are not boring.
The Healthcare Trades That Actually Carry Weight
Step back from the last 90 days and look at the full picture. Hern's disclosure history includes several trades in companies that fall squarely inside his committee's jurisdiction.
In June 2024, he purchased UnitedHealth Group (UNH) in the $1,000 to $15,000 range. Thirty-day alpha: 12.8 percentage points above the S&P 500. UNH is a healthcare company. Hern's subcommittee is Health. That overlap is flagged in the filings. He sold UNH in December 2025 in the $250,000 to $500,000 range, capturing a modest 2.0 percentage points of 30-day alpha on the exit. The Bluesky tracking accounts noticed that UNH sale: disclosed 30 days after the trade cleared.
In July 2024, he bought Chubb (CB) in the $1,000 to $15,000 range. Thirty-day alpha: 13.3 points. Chubb is an insurance company. Ways and Means Health touches insurance. Flagged as a committee overlap.
In March 2024, he bought Johnson & Johnson (JNJ) in the $1,000 to $15,000 range. Flagged as a pharmaceuticals overlap. That one went nowhere: negative 0.2 points of alpha in 30 days. Not every committee-adjacent trade prints.
In October 2025, he sold Boston Scientific (BSX) in the $15,000 to $50,000 range. Healthcare overlap. Negative 0.4 points of alpha. A small loss on the exit.
The pattern: Hern trades in sectors his committee oversees. Sometimes it works. Sometimes it doesn't. The system permits all of it.
The Full Scorecard
Across 74 scored trades in the disclosed record, Hern is 31 positive and 43 negative. Mean 30-day alpha: negative 1.0 percent. The best single trade in the sample was that CB purchase at plus 13.3 points. The worst was a sale of BNPQY in October 2025, in the $1,000,000 to $5,000,000 range, at negative 14.1 points of alpha — he also sold BNPQY the same day in the $250,000 to $500,000 range at the same loss. A big exit that cost him relative to holding the index.
In March 2026, a sale of Progress Software (PRGS) in the $50,000 to $100,000 range came in at negative 20.3 points of 30-day alpha. The single worst outcome in the sample.
More losses than wins, negative mean alpha, a couple of standout gains in committee-adjacent names. Readers can decide how to weigh that.
The Disclosure Clock
Members of Congress are required to disclose their trades within 45 days of execution under the STOCK Act. They are not required to recuse themselves from votes or committee work that touches the companies they own. They are not required to explain the timing, the rationale, or the relationship between their portfolio and their legislative agenda.
The Bluesky accounts that track these filings have flagged Hern's disclosures multiple times in recent months: DVN disclosed 15 days late, ACN 20 days late, and the UNH sale a full 30 days after the trade cleared. All within the 45-day window. Whether that window is the right one for the public to know what their representative is doing with their money is a policy question nobody in the building seems eager to revisit.
Recent Votes: The Floor Record
Hern's recent vote history skews toward financial-sector and veterans legislation. He voted Yea on the TRIA Program Reauthorization Act on June 29, which touches terrorism risk insurance. He voted Yea on the Financial Exploitation Prevention Act on June 25. Both cleared the floor.
None of those floor votes map directly to a committee-level conflict with his disclosed holdings. The TRIA program lives under Financial Services jurisdiction, not Ways and Means. Floor votes are floor votes. His committee jurisdiction is Ways and Means: taxes, trade, health financing. That's the line.
The Acute-Care Bill and the Larger Question
H.R. 9468 will go to committee. Whether it moves is a function of leadership priorities and the legislative calendar. As a standalone bill introduced by a subcommittee member in his own policy lane, its odds are what most standalone bills face: low, but not zero.
Hern's full disclosure record is public. His committee assignments are public. His vote history is public. The trades are public, down to the date and the range. All of it's here for anyone who wants to read the receipts.
Take that for what it's worth.